Pasithea Therapeutics Corp
KTTA1.160USD
+0.060+5.45%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
8.63MMarket Cap
LossP/E TTM
More Details of Pasithea Therapeutics Corp Company
Pasithea Therapeutics Corp. is a biotechnology company focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases. The Company is advancing a pipeline of three therapeutic product candidates, with a focus on its lead product candidate, PAS-004, a macrocyclic mitogen-activated protein kinase, or MEK inhibitor. PAS-004 is a small molecule allosteric inhibitor of MEK 1 and 2 (MEK 1/2) for potential use in the treatment of a range of RASopathies, including neurofibromatosis type 1 (NF1) and a number of oncology indications, among others. Its remaining two programs, PAS-001 and PAS-003, are in the earlier stages of development and are based on novel targets for the treatment of CNS disorders that it believes address limitations in the treatment paradigm of the indications it plans to address, which are amyotrophic lateral sclerosis (ALS) for its PAS-003 program, and schizophrenia for its PAS-001 program.
Pasithea Therapeutics Corp Info
Ticker SymbolKTTA
Company namePasithea Therapeutics Corp
IPO dateAug 13, 2021
CEOMarques (Tiago Reis)
Number of employees4
Security typeOrdinary Share
Fiscal year-endAug 13
Address1111 Lincoln Road, Suite 500
CityMIAMI BEACH
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code33139
Phone17025144174
Websitehttps://www.pasithea.com/
Ticker SymbolKTTA
IPO dateAug 13, 2021
CEOMarques (Tiago Reis)
Company Executives of Pasithea Therapeutics Corp
Name
Name/Position
Position
Shareholding
Change
Prof. Lawrence Steinman, M.D.
Prof. Lawrence Steinman, M.D.
Executive Chairman, Co-Founder
Executive Chairman, Co-Founder
199.69K
+200.93%
Dr. Tiago Reis Marques
Dr. Tiago Reis Marques
Chief Executive Officer, Director
Chief Executive Officer, Director
73.33K
+83.33%
Mr. Simon Dumesnil
Mr. Simon Dumesnil
Independent Director
Independent Director
35.83K
+1333.32%
Dr. Emer Leahy, Ph.D.
Dr. Emer Leahy, Ph.D.
Independent Director
Independent Director
33.33K
--
Mr. Daniel H. Schneiderman
Mr. Daniel H. Schneiderman
Chief Financial Officer
Chief Financial Officer
26.67K
--
Mr. Alfred J. Novak
Mr. Alfred J. Novak
Independent Director
Independent Director
3.50K
--
Mr. Patrick Gaynes
Mr. Patrick Gaynes
Investor Relations
Investor Relations
--
--
Name
Name/Position
Position
Shareholding
Change
Prof. Lawrence Steinman, M.D.
Prof. Lawrence Steinman, M.D.
Executive Chairman, Co-Founder
Executive Chairman, Co-Founder
199.69K
+200.93%
Dr. Tiago Reis Marques
Dr. Tiago Reis Marques
Chief Executive Officer, Director
Chief Executive Officer, Director
73.33K
+83.33%
Mr. Simon Dumesnil
Mr. Simon Dumesnil
Independent Director
Independent Director
35.83K
+1333.32%
Dr. Emer Leahy, Ph.D.
Dr. Emer Leahy, Ph.D.
Independent Director
Independent Director
33.33K
--
Mr. Daniel H. Schneiderman
Mr. Daniel H. Schneiderman
Chief Financial Officer
Chief Financial Officer
26.67K
--
Mr. Alfred J. Novak
Mr. Alfred J. Novak
Independent Director
Independent Director
3.50K
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Wed, Dec 10
Updated: Wed, Dec 10
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Squadron Capital Management LLC
9.42%
Vivo Capital, LLC
8.56%
Orca Capital GmbH
1.63%
AdvisorShares Investments, LLC
1.16%
Steinman (Lawrence)
0.90%
Other
78.34%
Shareholders
Shareholders
Proportion
Squadron Capital Management LLC
9.42%
Vivo Capital, LLC
8.56%
Orca Capital GmbH
1.63%
AdvisorShares Investments, LLC
1.16%
Steinman (Lawrence)
0.90%
Other
78.34%
Shareholder Types
Shareholders
Proportion
Investment Advisor
12.60%
Venture Capital
8.71%
Individual Investor
1.67%
Hedge Fund
0.70%
Research Firm
0.23%
Investment Advisor/Hedge Fund
0.11%
Other
75.98%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
31
804.10K
10.80%
-113.25K
2025Q2
33
1.23M
18.27%
+454.62K
2025Q1
32
331.02K
5.61%
-460.75K
2024Q4
30
322.63K
25.48%
-746.50K
2024Q3
36
1.59M
35.25%
-4.18M
2024Q2
34
1.50M
26.15%
-4.28M
2024Q1
35
1.50M
29.85%
-8.78M
2023Q4
34
6.19M
23.97%
-3.95M
2023Q3
36
7.48M
28.68%
-4.88M
2023Q2
34
7.60M
28.90%
-4.79M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Orca Capital GmbH
362.86K
4.87%
+362.86K
--
May 07, 2025
AdvisorShares Investments, LLC
193.55K
2.6%
+140.00K
+261.45%
Jun 30, 2025
Steinman (Lawrence)
66.36K
0.89%
--
--
Jul 22, 2025
Marques (Tiago Reis)
40.00K
0.54%
+460.00
+1.16%
Jul 22, 2025
Citadel Advisors LLC
46.86K
0.63%
+46.86K
--
Jun 30, 2025
The Vanguard Group, Inc.
9.27K
0.12%
--
--
Aug 31, 2025
Dumesnil (Simon)
2.50K
0.03%
--
--
Jul 22, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
AdvisorShares Psychedelics ETF
1.36%
AdvisorShares Psychedelics ETF
Proportion1.36%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Dec 28, 2023
Merger
20→1
Dec 28, 2023
Merger
20→1
Dec 28, 2023
Merger
20→1
Dec 28, 2023
Merger
20→1
Date
Type
Ratio
Dec 28, 2023
Merger
20→1
Dec 28, 2023
Merger
20→1
Dec 28, 2023
Merger
20→1
Dec 28, 2023
Merger
20→1
FAQs
Who are the top five shareholders of Pasithea Therapeutics Corp?
The top five shareholders of Pasithea Therapeutics Corp are:
Orca Capital GmbH holds 362.86K shares, accounting for 4.87% of the total shares.
AdvisorShares Investments, LLC holds 193.55K shares, accounting for 2.60% of the total shares.
Steinman (Lawrence) holds 66.36K shares, accounting for 0.89% of the total shares.
Marques (Tiago Reis) holds 40.00K shares, accounting for 0.54% of the total shares.
Citadel Advisors LLC holds 46.86K shares, accounting for 0.63% of the total shares.
Orca Capital GmbH holds 362.86K shares, accounting for 4.87% of the total shares.
AdvisorShares Investments, LLC holds 193.55K shares, accounting for 2.60% of the total shares.
Steinman (Lawrence) holds 66.36K shares, accounting for 0.89% of the total shares.
Marques (Tiago Reis) holds 40.00K shares, accounting for 0.54% of the total shares.
Citadel Advisors LLC holds 46.86K shares, accounting for 0.63% of the total shares.
What are the top three shareholder types of Pasithea Therapeutics Corp?
The top three shareholder types of Pasithea Therapeutics Corp are:
Squadron Capital Management LLC
Vivo Capital, LLC
Orca Capital GmbH
Squadron Capital Management LLC
Vivo Capital, LLC
Orca Capital GmbH
How many institutions hold shares of Pasithea Therapeutics Corp (KTTA)?
As of 2025Q3, 31 institutions hold shares of Pasithea Therapeutics Corp, with a combined market value of approximately 804.10K, accounting for 10.80% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -7.46%.
What is the biggest source of revenue for Pasithea Therapeutics Corp?
In --, the -- business generated the highest revenue for Pasithea Therapeutics Corp, amounting to -- and accounting for --% of total revenue.
